Reference Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

Ref Type Journal Article
PMID (27919942)
Authors Hancock BM, McGuire KL, Tsuji S, Reil K, Hernandez V, Giacalone MJ, Godbey WT
Title A Single Intravesical Instillation of VAX014 Inhibits Orthotopic Superficial Bladder Tumor Implantation to Increase Survival.
Journal Anticancer research
Vol 36
Issue 12
Date 2016 12
Abstract Text VAX014 minicells (VAX014) have been previously characterized as an integrin-specific oncolytic biotherapeutic agent. The present study was designed to evaluate the potential of VAX014 as an immediate post-operative intravesical adjuvant therapy in the treatment of non-muscle invasive bladder cancer (NMIBC).The ability of VAX014 to kill a panel of dissociated urothelial carcinoma cell lines was tested in vitro. In vivo experiments were conducted using a single intravesical dose of VAX014 in the anti-implantation variation of the MB49 syngeneic orthotopic bladder cancer model with tumor implantation and overall survival rates serving as study endpoints.VAX014 rapidly killed dissociated urothelial carcinoma cells, while single dose in vivo pharmacology studies demonstrated the dose-dependent ability of VAX014 to prevent tumor implantation and development, ultimately resulting in a significant survival advantage compared to controls.These results suggest that VAX014 holds potential as an immediate post-operative adjuvant therapy in NMIBC.


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Drug Name Trade Name Synonyms Drug Classes Drug Description
VAX014 VAX-IP|VAX 014|VAX-014 VAX014 is bacterial minicell therapeutic comprising E. coli engineered to express Invasin and the bacterial toxin perfringolysin O (PFO), which delivers the toxin to tumor cells expressing Integrin alpha3beta1 or alpha5beta1, potentially resulting in increased tumor cell apoptosis and decreased tumor growth (PMID: 27919942, PMID: 27119118).
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown bladder urothelial carcinoma not applicable VAX014 Preclinical Actionable In a preclinical study, VAX014 induced cell-killing in dissociated mouse and human urothelial carcinoma cell lines in culture, and inhibited tumor growth and improved survival in a syngeneic bladder cancer model (PMID: 27919942). 27919942